Clene’s (CLNN) Buy Rating Reaffirmed at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Clene (NASDAQ:CLNN) in a report released on Thursday,Benzinga reports. D. Boral Capital currently has a $23.00 price objective on the stock.

Several other equities analysts also recently issued reports on the stock. Canaccord Genuity Group dropped their price target on shares of Clene from $86.00 to $83.00 and set a “buy” rating for the company in a research note on Thursday, November 14th. HC Wainwright restated a “buy” rating and issued a $31.00 price objective on shares of Clene in a report on Thursday, November 14th. Finally, Benchmark cut their target price on Clene from $90.00 to $84.00 and set a “buy” rating on the stock in a report on Friday, November 22nd. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $55.25.

Clene Stock Down 4.5 %

NASDAQ:CLNN opened at $4.42 on Thursday. The stock’s 50-day simple moving average is $4.79 and its 200 day simple moving average is $5.05. Clene has a twelve month low of $3.82 and a twelve month high of $10.65.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in CLNN. Castleview Partners LLC acquired a new position in shares of Clene in the 3rd quarter valued at about $59,000. Parsons Capital Management Inc. RI purchased a new stake in shares of Clene in the fourth quarter worth approximately $194,000. Finally, SBI Securities Co. Ltd. purchased a new stake in shares of Clene in the fourth quarter worth approximately $69,000. 23.28% of the stock is owned by institutional investors and hedge funds.

About Clene

Clene Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.